Researchers have uncovered and then overcome an obstacle that has led to the failure of pioneering efforts in ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that the company has dosed the first patient in the SYNERGY-101 study. SYNERGY-101 is a global, randomized Phase 2 ...

Securing a reliable supply of electricity requires plenty of research to balance the risks and rewards of striking a deal.

Yesterday at the Ernest N Morial Convention Center, latest clinical trial findings were disclosed on the use of human engineered heart muscle as biological ventricular assist tissue (BioVAT) ...

The U.S. Food & Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS® (zongertinib tablets), currently under investigation for first-line use in ...